The Patent Finder

Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function

Otsuka Pharmaceutical Co., Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 4 of these applications claim priority to application 14/034,727, filed Sep 24, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,980,803Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
In force
 · High confidence
Otsuka Pharmaceutical Co., Ltd.In force
High confidence
US 11,154,553Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
In force
 · High confidence
Otsuka Pharmaceutical Co., Ltd.In force
High confidence
US 11,344,547Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
In force
 · High confidence
Otsuka Pharmaceutical Co., Ltd.In force
High confidence
US 11,400,087Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
In force
 · High confidence
Otsuka Pharmaceutical Co., Ltd.In force
High confidence
US 10,525,057Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
In force
 · High confidence
Otsuka Pharmaceutical Co., Ltd.In force
High confidence
Application 17/206,241Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
Abandoned
Abandoned Jul 19, 2023
Otsuka Pharmaceutical Co., Ltd.AbandonedAbandoned Jul 19, 2023
Application 17/731,494Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Function
Abandoned
Abandoned Feb 24, 2025
Otsuka Pharmaceutical Co., Ltd.AbandonedAbandoned Feb 24, 2025
Application 19/053,509Method of Providing Aripiprazole to Patients Having Impaired CYP2D6 or CYP3A4 Enzyme Fuction
Pending
Not granted
Otsuka Pharmaceutical Co., Ltd.PendingNot granted
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Otsuka Pharmaceutical Co., Ltd..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited